1. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability.
- Author
-
Jiang, Wenna, Liu, Lin, Wang, Meng, Li, Xueyang, Zhou, Tianxing, Hou, Xupeng, Qiao, Lu, Chen, Chong, Zuo, Duo, Liu, Jing, and Ren, Li
- Subjects
CANCER stem cells ,PANCREATIC duct ,TUMOR classification ,DEUBIQUITINATING enzymes ,PANCREATIC cancer - Abstract
The existence of cancer stem cells (CSCs) in pancreatic ductal adenocarcinoma (PDAC) is considered to be the key factor for metastasis and chemoresistance. Thus, novel therapeutic strategies for eradicating CSCs are urgently needed. Here we aimed to explore the role of KLF15 in stemness and the feasibility of using KLF15 to inhibit CSCs and improve chemotherapy sensitivity in PDAC. In this study, we report that KLF15 is negatively associated with poor survival and advanced pathological staging of PDAC. Moreover, tumorous KLF15 suppresses the stemness of PDAC by promoting the degradation of Nanog, and KLF15 directly interacts with Nanog, inhibiting interaction between Nanog with USP21. We also demonstrate that the KLF15/Nanog complex inhibit the stemness in vivo and in PDX cells. Tazemetostat suppresses stemness and sensitizes PDAC cells to gemcitabine by promoting KLF15 expression in PDAC. In summary, the findings of our study confirm the value of KLF15 level in diagnosis and prognosis of PDAC, it is the first time to explore the inhibition role of KLF15 in stemness of PDAC and the regulation mechanism of Nanog, contributing to provide a new therapeutic strategy that using Tazemetostat sensitizes PDAC cells to gemcitabine by promoting KLF15 expression for PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF